Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

23.10.15	Press Release: Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis (Dow Jones)
21.10.15	Press Release: Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma (Dow Jones)
15.10.15	Press Release: Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases (Dow Jones)
10.10.15	Press Release: Novartis presents new data showing -2- (Dow Jones)
10.10.15	Press Release: Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years (Dow Jones)
08.10.15	Press Release: Novartis: Long-term efficacy of -2- (Dow Jones)
08.10.15	Press Release: Novartis: Long-term efficacy of Gilenya(R) reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years (Dow Jones)
05.10.15	Press Release: Novartis: Alcon receives FDA -2- (Dow Jones)
05.10.15	Press Release: Novartis: Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery (Dow Jones)
02.10.15	Press Release: Novartis: FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept (Dow Jones)
01.10.15	Press Release: Novartis announces NEJM -2- (Dow Jones)
30.09.15	Press Release: Novartis announces NEJM -2- (Dow Jones)
30.09.15	Press Release: Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis (Dow Jones)
28.09.15	Press Release: Patients with aggressive form of -3- (Dow Jones)
28.09.15	Press Release: Patients with aggressive form of -2- (Dow Jones)
28.09.15	Press Release: Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar(R) + Mekinist(R) (Dow Jones)
27.09.15	Press Release: Novartis drug Afinitor(R) -2- (Dow Jones)
27.09.15	Press Release: Novartis drug Afinitor(R) significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET (Dow Jones)
25.09.15	Press Release: Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval (Dow Jones)
24.09.15	GlobeNewswire/Novartis ernennt Dr. James E. Bradner zum Präsidenten der Novartis Institutes for BioMedical Research, da Mark Fishman in den Ruhestand tritt (Dow Jones)
24.09.15	GlobeNewswire/Novartis nomme le Dr James E. Bradner Président des Instituts Novartis pour la Recherche Biomédicale suite au prochain départ à la retraite ... (Dow Jones)
24.09.15	Press Release: Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires (Dow Jones)
24.09.15	GlobeNewswire/Novartis lanciert "Novartis Access", ein Portfolio von erschwinglichen Medikamenten zur Behandlung von chronischen Erkrankungen in Ländern m... (Dow Jones)
24.09.15	GlobeNewswire/Novartis lance Novartis Access >>, une gamme de médicaments à prix abordables pour lutter contre les maladies chroniques dans les pays à fai... (Dow Jones)
24.09.15	Press Release: Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries (Dow Jones)
18.09.15	Press Release: Swissmedic approves Novartis' new heart failure medicine Entresto(TM) (Dow Jones)
07.09.15	Press Release: Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH (Dow Jones)
04.09.15	Press Release: Novartis receives EU approval for -2- (Dow Jones)
04.09.15	Press Release: Novartis receives EU approval for Farydak(R), the first in its class of anticancer agents approved for patients with multiple myeloma (Dow Jones)
03.09.15	Press Release: Novartis: Sandoz launches ZarxioTM -2- (Dow Jones)
03.09.15	Press Release: Novartis: Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States (Dow Jones)
02.09.15	Press Release: Novartis receives EU approval for -2- (Dow Jones)
02.09.15	Press Release: Novartis receives EU approval for new Revolade(R) use as first-in-class therapy for patients with severe aplastic anemia (Dow Jones)
01.09.15	Press Release: Novartis announces global -2- (Dow Jones)
01.09.15	Press Release: Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments (Dow Jones)
01.09.15	Press Release: Novartis receives EU approval for -3- (Dow Jones)
01.09.15	Press Release: Novartis receives EU approval for -2- (Dow Jones)
01.09.15	Press Release: Novartis receives EU approval for Tafinlar(R) and Mekinist(R), first combination approved for patients with aggressive form of melanoma (Dow Jones)
28.08.15	Press Release: Novartis continues commitment to -2- (Dow Jones)
28.08.15	Press Release: Novartis continues commitment to go the last mile in effort to eliminate leprosy (Dow Jones)
24.08.15	Press Release: FDA expands use of Novartis drug -3- (Dow Jones)
24.08.15	Press Release: FDA expands use of Novartis drug -2- (Dow Jones)
24.08.15	Press Release: FDA expands use of Novartis drug Promacta(R) to include treatment of children ages 1 and older with chronic immune thrombocytopenia (Dow Jones)
21.08.15	Press Release: Novartis acquires all remaining -2- (Dow Jones)
21.08.15	Press Release: Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications (Dow Jones)
20.08.15	Press Release: Novartis drug Odomzo(R) gains EU -2- (Dow Jones)
20.08.15	Press Release: Novartis drug Odomzo(R) gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients (Dow Jones)
03.08.15	Press Release: Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million (Dow Jones)
29.07.15	Press Release: Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd (Dow Jones)
27.07.15	Press Release: Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt (Dow Jones)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt